Product Details
| Product Name:
ZLN024 |
CAS No.:
723249-01-2 |
| Purity:
99.82% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | ZLN024 |
| Description | ZLN024 is an activator of AMPK allosteric. ZLN024 allosterically stimulates active AMPK heterotrimers and the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312). |
| In vitro | ZLN024 allosterically stimulates active AMPK heterotrimers and the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312). It increases the activity of α1β1γ1 by 1.5-fold with an EC50 of 0.42 μM, α2β1γ1 by 1.7-fold with an EC50 of 0.95 μM, recombinant AMPK α1β2γ1 by 1.7-fold with an EC50 of 1.1 μM, and AMPK α2β2γ1 by 1.6-fold with an EC50 of 0.13 μM. |
| In vivo | C57BKS db/db mice are administered a 15 mg/kg/day dose of ZLN024 by daily gavage for 5 weeks; 250 mg/kg/day Metformin (Met) is used as a positive control. After 4 weeks of treatment, ZLN024 improves glucose tolerance, reduces fasting blood glucose by 15%, and decreases liver tissue weight, triacylglycerol, and total cholesterol content. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/ml (153.74 mM)
|
| Keywords | ZLN-024 | ZLN024 | ZLN 024 | Inhibitor | inhibit | AMPK | AMP-activated protein kinase |
| Inhibitors Related | Phenformin hydrochloride | AICAR | Doxorubicin hydrochloride | Adenosine monophosphate | Adenosine 5'-monophosphate monohydrate | Metformin | Methyl cinnamate | A-769662 | Metformin hydrochloride | Chitosan oligosaccharide | Buformin hydrochloride | HTH-01-015 |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Glutamine Metabolism Compound Library | Hematonosis Compound Library | Neuroprotective Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1807534-85-5
$43.00 / 5mg
-
CAS:1510712-69-2
$79.00 / 1mg
-
CAS:1426174-41-5
$2570.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$89.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States